Circadian Depression: When the Body Clock and Mood Fall Out of Step

Imagine a 24-year-old graduate student referred for a third antidepressant trial. Her mood sinks every November and lifts in March. On weekends she sleeps until noon, and on weekdays she cannot think clearly until mid-morning. Two selective serotonin reuptake inhibitors produced drowsiness and little else. Nothing in her chart records her sleep, and no one has asked.

A recent Scientific American article argues that patients like her may belong to a subgroup whose depression travels with a disrupted body clock. The article spotlights a British Journal of Psychiatry study, published this month, that proposed a “circadian” profile linked to earlier onset, more severe symptoms, and lower self-reported antidepressant benefit. The findings deserve attention, but they do not establish a new diagnosis or show that circadian disruption causes depression. This post explains what the study found, its limits, and how clinicians and counselors can use the idea responsibly (Dhar, 2026; Tonini et al., 2026).

The body clock shapes more than sleep

A circadian rhythm is a roughly 24-hour pattern in a biological process. The master pacemaker sits in the suprachiasmatic nucleus (SCN) of the hypothalamus, which receives light information from specialized retinal cells and relays timing signals to clocks in nearly every tissue. Through those signals, the system coordinates sleep and wakefulness, core body temperature, cortisol, melatonin, appetite, and glucose metabolism.

The SCN (orange) sits above the optic chiasm.

Light is the dominant cue, and its effect depends on when it arrives relative to a person’s internal phase: for most people, morning light advances the clock and late-evening light delays it (Fishbein et al., 2021).

The clock also listens to behavior. Meals, activity, and social schedules shape daily rhythms, though irregular timing does not rule out a sleep, psychiatric, or medical condition. Circadian misalignment occurs when internal timing and the external schedule disagree, as in shift work or jet lag. Psychophysiologists will recognize the broader point: physiology keeps time (Fishbein et al., 2021).

Sleep timing and depression can influence each other. A late or irregular schedule can undermine sleep, daily functioning, and mood, while depression can itself alter sleep, energy, activity, and the hour a person feels able to get up. Neither direction is the whole story.

Chronotype, social jetlag, and the night owl question

Researchers use chronotype to describe a person’s habitual preference for earlier or later sleep and activity. The Morningness-Eveningness Questionnaire asks about preferred times for sleep, waking, and demanding work, and scores respondents from definite morning type to definite evening type. The Munich ChronoType Questionnaire instead records actual bed and wake times on workdays and free days. It uses the free-day sleep midpoint as a behavioral marker of internal timing (Horne & Östberg, 1976; Roenneberg et al., 2003).

That second approach yields a useful derived measure. Social jetlag is the difference between mid-sleep time on workdays and on free days, and it serves as a proxy for mismatch between a person’s schedule and their internal timing.

Picture a night owl who sleeps from 11:30 p.m. to 6:30 a.m. on workdays and from 1:30 a.m. to 10:30 a.m. on free days. The workday midpoint falls at 3:00 a.m. and the free-day midpoint at 6:00 a.m., for three hours of social jetlag. Being an evening type is not an illness. Concern grows when the preferred schedule collides repeatedly with work, school, or caregiving, or when sleep and mood symptoms cause impairment (Roenneberg et al., 2003).

Does eveningness raise the risk of depression? A prospective study followed 32,470 women in the Nurses’ Health Study II for four years. After multivariable adjustment, early chronotypes had a modestly lower hazard of incident depression than intermediate types (hazard ratio, 0.88). Late chronotypes did not differ significantly from intermediate types in this cohort of middle-aged and older women (Vetter et al., 2018).

Genetic evidence points in the same direction. In a Mendelian randomization analysis drawing on more than 697,000 people, a genetic tendency toward a one-hour-earlier sleep midpoint was associated with 23% lower odds of major depression. The finding is compatible with a causal contribution of timing to mood. It does not show that moving a patient’s bedtime earlier would prevent depression, and the result may not extend to extreme phenotypes such as delayed sleep-wake phase disorder (Daghlas et al., 2021).

Treatment studies carry a similar message. In a systematic review, 23 of 58 included studies examined the association between circadian realignment and depression. Improvement accompanied realignment in studies that enrolled people with baseline delays and elevated symptoms, but the reviewers rated average study quality as fair. Trials that measure circadian phase are needed to test whether realignment itself improves mood (Wescott et al., 2025).

Chronotype is a dimension, not a diagnosis. Epidemiological and genetic data link later timing with somewhat greater depression risk at the population level, but the effects are modest. The clinical meaning for one patient depends on sleep quality, impairment, and the fit between internal timing and external demands.

Where the circadian depression idea came from

The Australian study didn't appear out of nowhere. In 2021, Ian Hickie’s group at the University of Sydney proposed circadian depression as a clinical phenotype marked by disrupted sleep-wake cycles, reduced motor activity, low energy, and weight gain. They described early onset, bipolar-like swings in activity and mood, poor response to standard antidepressants, and cardiometabolic and inflammatory disturbances.

The 2026 study is the first large-scale attempt to operationalize that proposal. Testing one’s own hypothesis is legitimate science, but it also means that independent replication by other groups matters more than usual (Carpenter et al., 2021; Tonini et al., 2026).

What the Australian study found

Tonini and colleagues analyzed survey and genetic data from 11,380 adults with a history of depression in the Australian Genetics of Depression Study. All participants were of genetically inferred European ancestry, about 75% were women, and the average age was 43.8 years. The researchers classified 2,604 participants, or 23%, as having the proposed circadian profile because they met at least three of six criteria. The cutoff was provisional, and all six criteria carried equal weight (Tonini et al., 2026).

The six criteria deserve a close look because clinicians will recognize the instruments. Seasonality meant a Global Seasonality Score of 11 or higher on the Seasonal Pattern Assessment Questionnaire. Delayed timing meant a free-day sleep midpoint later than an age-specific cutoff: roughly 6 a.m. for ages 18 to 24 and 4:30 a.m. for ages 65 and older. Social jetlag meant a free-day midpoint later than the workday midpoint by an age-specific margin, from 2.5 hours in young adults to 1.25 hours in older adults (Tonini et al., 2026).

The remaining three criteria came from single questionnaire items. Evening chronotype meant endorsing “definitely an evening type” on the Morningness-Eveningness Questionnaire. Hypersomnia meant sleeping much more than usual during the worst depressive episode, drawn from the DSM-5 symptom list. Morning tiredness rested on one item, feeling “very tired” in the first half hour after waking; the authors noted that future work should measure a construct closer to sleep inertia. Note also that hypersomnia was assessed during an episode, while the other criteria described habitual patterns (Tonini et al., 2026).

Within the circadian group, the criteria were far from equally common. Hypersomnia (84%) and morning tiredness (83%) were nearly universal, evening chronotype (68%) was common, and delayed sleep midpoint (42%), seasonality (41%), and social jetlag (35%) were each met by a minority. The typical member of this group, then, was a self-described night owl who sleeps heavily when depressed and wakes up exhausted (Tonini et al., 2026).

Roughly one in four participants met the three-of-six rule, but that number does not estimate how common circadian depression is in the general population. It describes a subgroup within a selected cohort of adults with a history of depression, defined by six exploratory features and a provisional threshold.

The profile was associated with a more severe self-reported symptom picture and an earlier recalled age at onset. Circadian cases were younger on average (37.9 versus 45.6 years), more often women, and recalled onset at 18.7 versus 23.2 years. They scored higher on psychological distress, somatic distress, and suicidal ideation, and more often reported hypomanic-like and psychotic-like experiences. Weight gain during episodes was more common, and 12% reported a bipolar disorder diagnosis compared with 9% of other participants (Tonini et al., 2026).

These are group-level, cross-sectional associations from self-report. They cannot establish a longitudinal course, and they do not show that circadian problems caused the differences. Several criteria, especially hypersomnia and morning exhaustion, are themselves depression symptoms. A rule that selects for those features will also select for more severe illness, so part of the association may be built into the definition (Tonini et al., 2026).

The genetic results add texture without settling causation. The circadian group had slightly higher polygenic risk scores for ADHD, major depression, anxiety, and bipolar disorder, with odds ratios between 1.09 and 1.11. They also carried modestly higher genetic liability for body mass index, triglycerides, interleukin-6, insulin resistance, insomnia, and later sleep midpoint. Nominal associations with coronary artery disease, type 2 diabetes, and schizophrenia did not survive correction for multiple comparisons (Tonini et al., 2026).

A polygenic risk score summarizes many common variants linked to a trait in other studies. It is not a diagnostic test, and these results do not show that participants had the related illnesses. The surviving pattern suggests shared genetic liability with some metabolic and inflammatory traits, in line with the 2021 proposal. It does not establish clinical disease or future cardiometabolic risk in this group (Carpenter et al., 2021; Tonini et al., 2026).

How far can the findings carry?

The study is cross-sectional. It measured features at one time rather than following people to learn which changes came first. Participants recalled symptoms and treatment experiences, sometimes from years earlier, and no one measured clock timing with a phase marker such as melatonin onset. The authors stated these limits plainly, described the criteria as provisional and exploratory, and called for independent replication (Tonini et al., 2026).

The criteria also mix different kinds of information. A person can reach the threshold through several combinations of seasonality, evening preference, exhausted mornings, and hypersomnia, and those combinations may not share one biological mechanism. When the authors excluded participants who did not meet self-rated criteria for major depression, three genetic findings and one treatment finding weakened. The ancestry restriction further limits generalization. A fair reading is that the profile is a promising research signal that now needs prospective, objectively measured, and independently replicated tests (Tonini et al., 2026; Wescott et al., 2025).

What the antidepressant finding does and does not mean

Participants in the circadian group reported lower benefit from selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors, with odds ratios of 0.88 and 0.89. Mirtazapine and amitriptyline showed no significant difference. The group also reported more side effects, including fatigue, drowsiness, difficulty sleeping, weight gain, anxiety, and nausea. These were retrospective self-ratings, not trial outcomes from a medication-assignment study (Tonini et al., 2026).

The result echoes an earlier analysis of 15,108 participants from the same cohort. There, higher self-rated eveningness predicted poorer self-reported efficacy for escitalopram, citalopram, fluoxetine, sertraline, and desvenlafaxine, with odds ratios of about 1.02 to 1.04 per scale point. Because the two analyses share participants, the earlier report is overlapping evidence rather than independent replication. A separate Australian survey had also linked evening preference with lower self-reported SSRI benefit (Crouse et al., 2024; McGlashan et al., 2018).

Three cautions apply. The effects are small, the measures are self-reports open to recall and expectation bias, and none of these studies tested whether a different treatment would have worked better. A night owl who has not improved on sertraline may need a dose adjustment, a different class, psychotherapy, or attention to an untreated sleep disorder. The findings support taking a sleep-timing history, but they do not show that chronotype predicts which medication to try next (Crouse et al., 2024; Tonini et al., 2026).

Clinicians should read these findings as a reason to ask better questions about timing, not as a reason to label night owls, change medication on the strength of a survey, or assume that a patient’s depression has a circadian cause.

The bipolar-spectrum watch

The circadian group reported more hypomanic-like and psychotic-like experiences, earlier onset, hypersomnia, weight gain, and more bipolar diagnoses. That cluster overlaps considerably with atypical and bipolar-spectrum depression, and Hickie’s group has long argued that the two are related. The clinical implication is screening. Before recommending a higher-risk intervention such as bright light or wake therapy, ask about past periods of decreased need for sleep, elevated or irritable mood, racing thoughts, and risky behavior. Ask about family history of bipolar disorder as well (Carpenter et al., 2021; Tonini et al., 2026).

Bright light and wake therapy carry a risk of hypomanic switching in vulnerable patients. The International Society for Bipolar Disorders task force recommends morning or midday light with clinical monitoring and antimanic prophylaxis, especially in bipolar I disorder. Acute or recent mania or hypomania, mixed symptoms, and rapid cycling are contraindications to light therapy (Geoffroy et al., 2025; Gottlieb et al., 2019).

Assessing timing in practice

A practical assessment takes five minutes. Ask when the patient naturally falls asleep and wakes on free days, how those times differ on workdays, and whether mood shifts with the seasons. Ask whether morning exhaustion persists despite adequate sleep, and when the patient feels most alert and most impaired. These questions map onto the Australian criteria and the Munich and Morningness-Eveningness questionnaires, either of which can be added to intake paperwork (Horne & Östberg, 1976; Roenneberg et al., 2003; Tonini et al., 2026).

A two-week sleep diary turns impressions into data. When history is unclear, or self-report is unreliable, wrist actigraphy adds objective estimates of sleep timing and regularity. The American Academy of Sleep Medicine supports its use for evaluating circadian rhythm sleep-wake disorders. Consumer wearables offer a rough approximation, though their algorithms are proprietary and their accuracy varies (Smith et al., 2018).

The reference phase marker is dim light melatonin onset (DLMO), the clock time at which melatonin begins to rise under dim light, measured from serial saliva samples. Some sleep specialists argue for measuring DLMO before treating circadian rhythm sleep disorders, because light or melatonin given at the wrong phase can fail or push the clock the wrong way.

In practice, DLMO can clarify phase when a phase-sensitive treatment is being considered; it is not a prerequisite for assessment or treatment, and testing is not routine in mental health settings (Keijzer et al., 2014).

Delayed sleep-wake phase disorder should stay on the differential. The diagnosis requires a stably delayed sleep schedule that causes distress or impairment for at least three months, and sleep that improves when the person can follow the delayed schedule. A diary or actigraphy should document timing for at least seven days. It frequently co-occurs with depression. Separating a delayed clock from insomnia, poor sleep habits, substance use, medication effects, or an episode that simply erodes mornings requires history, a diary, and sometimes a specialist (Auger et al., 2015).

The most defensible clinical use of this research is to make sleep timing and daily rhythms a routine part of depression assessment, especially when sleep-wake disruption is persistent or treatment has not helped enough. Timing observations can reveal a co-occurring sleep disorder or a schedule mismatch; they do not, on their own, diagnose the proposed subtype.

Treatment: keep claims proportionate to the evidence

Bright-light therapy has its strongest evidence in winter-pattern seasonal depression, where the U.S. National Institute of Mental Health describes it as a treatment option. Its reach is wider than many clinicians realize. A meta-analysis of 11 randomized trials involving 858 people with nonseasonal depressive disorders found remission in 40.7% of patients who received bright light versus 23.5% of controls, and response in 60.4% versus 38.6%. Most trials used 10,000 lux for 30 to 60 minutes daily, and several scheduled sessions soon after waking (Menegaz de Almeida et al., 2025; National Institute of Mental Health, n.d.).

Those trials did not select participants using the Australian criteria, so they cannot show that this subgroup benefits more than other patients. Guidance also varies in confidence. NICE advises clinicians to discuss the uncertainty about light therapy’s efficacy with people considering it instead of psychological or antidepressant treatment.

For bipolar depression, a randomized trial of 46 adults found 68% remission with 7,000-lux midday light versus 22% with dim red placebo, with no mood switches. That trial supports a carefully monitored midday regimen, but it did not compare midday with morning light and cannot show that one timing is safer (National Institute for Health and Care Excellence, 2022; Sit et al., 2018).

Chronotherapy refers to behavioral or pharmacological approaches intended to shift circadian timing, and timing is everything. Morning light advances the clock, evening light delays it, and low-dose melatonin taken in the late afternoon or early evening advances it.

For delayed sleep-wake phase disorder, the American Academy of Sleep Medicine gives a weak recommendation for strategically timed melatonin in adults, based on low-quality evidence, and no recommendation for light therapy alone (Auger et al., 2015; Fishbein et al., 2021).

Expectations should stay modest. In a trial of 116 adults with DLMO-confirmed delayed sleep-wake phase disorder, 0.5 mg of melatonin one hour before the desired bedtime, combined with behavioral sleep-wake scheduling in both arms, advanced sleep onset by 34 minutes relative to placebo. That was a trial for a sleep disorder, not for depression (Sletten et al., 2018).

Wake therapy, a night of total or partial sleep deprivation often combined with light and an advanced sleep schedule, can lift depression within days. A meta-analysis of 16 studies, four randomized trials and 12 open-label case series, reported a moderate effect in the trials at five to seven days, with 33% response versus 1.5% in control conditions. It reported short-term outcomes only and does not establish longer-term durability, and the evidence came largely from inpatient settings (Humpston et al., 2020).

For the typical outpatient, the lowest-risk starting points are behavioral: regular sleep-wake timing, daytime light exposure, and reduced light at night. The Australian authors proposed these elements, along with melatonin-targeted approaches, as possibilities for their subgroup pending further evidence; none has been tested in patients selected by the criteria.

Even daytime light calls for caution in bipolar disorder and in people with retinal disease or photosensitizing medication. The evidence does not support promoting light boxes or melatonin as profile-specific therapies, or substituting them for evidence-based depression care (Geoffroy et al., 2025; Tonini et al., 2026; Wescott et al., 2025).

Counselors can also help patients interpret the headlines. A patient who reads that night owls have a “different kind of depression” may conclude that medication is pointless or that their schedule explains everything. A proportionate message is that timing is a potentially modifiable contributor worth assessing.

The study does not establish whether this profile predicts response to standard treatment or to circadian-targeted therapy, so it should not be used to dismiss established depression care (Dhar, 2026; Tonini et al., 2026).

Integrative summary and five key takeaways

Circadian depression is a promising research idea because it links sleep-wake timing, mood, genetics, and treatment experience in a testable way. The Australian study provides a first operational profile, but the criteria need independent replication with objective phase markers, and the treatment implications remain unproven for this group. In the meantime, asking about timing costs nothing and can change what a clinician looks for.

1. The circadian group represented 23% of one depression cohort under an exploratory three-of-six rule, not 23% of the general population.

2. The study found associations with earlier onset, symptom severity, polygenic risk, and self-reported antidepressant response; it did not establish cause, prognosis, or individual treatment response.

3. Evening chronotype is a preference, not a disorder. Its clinical relevance depends on sleep quality, impairment, and the fit between internal timing and external schedules.

4. Bright light has randomized-trial support as an adjunct in nonseasonal and bipolar depression, but no trial has tested it in patients selected by the proposed criteria. Bipolar-spectrum screening should precede bright light or wake therapy.

5. The decisive tests will be prospective replication in diverse samples with objective circadian measures, and trials that ask whether the profile predicts better outcomes from circadian-targeted care.

Glossary

actigraphy: estimation of sleep and wake periods from movement recorded by a wrist-worn accelerometer over days or weeks; the American Academy of Sleep Medicine supports its use in evaluating circadian rhythm sleep-wake disorders.

bright-light therapy: treatment involving scheduled exposure to bright light, typically 10,000 lux for 30 to 60 minutes, used for winter-pattern seasonal depression and studied as an adjunct in nonseasonal depression.

chronotherapy: behavioral or pharmacological treatment intended to shift circadian timing, including timed light, timed melatonin, sleep scheduling, and wake therapy.

chronotype: a person’s habitual preference for earlier or later sleep and activity timing, measured by questionnaire or by free-day sleep midpoint.

circadian depression: a proposed clinical phenotype in which disrupted sleep-wake timing, low energy, reduced activity, and weight gain accompany depression; it remains provisional and requires independent validation.

circadian misalignment: a mismatch between internal circadian timing and external cues or demands, such as work schedules or travel across time zones.

circadian rhythm: a roughly 24-hour biological pattern, generated by internal clocks and synchronized mainly by light, that regulates sleep and many other daily processes.

delayed sleep-wake phase disorder: a circadian rhythm sleep-wake disorder in which habitual sleep and wake times are stably later than desired or required for at least three months, causing distress or impairment, with sleep improving when the delayed schedule can be followed.

dim light melatonin onset (DLMO): the clock time at which melatonin secretion begins to rise under dim-light conditions, measured from serial saliva or blood samples; the standard marker of circadian phase in clinical research.

hypersomnia: sleeping substantially more than usual or experiencing excessive sleepiness; in the Australian study, the criterion concerned increased sleep during the worst depressive episode.

melatonin: a pineal hormone whose evening rise signals biological night; exogenous melatonin can shift circadian timing when given at the appropriate phase.

Mendelian randomization: an analytic method that uses genetic variants as proxies for an exposure to test whether the exposure may causally influence an outcome; it remains vulnerable to pleiotropy and other biases.

Morningness-Eveningness Questionnaire (MEQ): a 19-item self-report scale that classifies respondents from definite morning type to definite evening type based on preferred timing of sleep and activity.

Munich ChronoType Questionnaire (MCTQ): a self-report instrument that records actual sleep timing on workdays and free days and derives chronotype from the free-day sleep midpoint.

polygenic risk score: a statistical summary of many genetic variants associated with a trait in other studies; it estimates population-level genetic liability and is not an individual diagnosis.

Seasonal Pattern Assessment Questionnaire (SPAQ): a self-report measure of seasonal variation in mood, sleep, appetite, and activity that yields a Global Seasonality Score; the Australian study used a score of 11 or higher as its seasonality criterion.

sleep inertia: the grogginess and impaired performance that follow waking; the Australian study used a single item about feeling very tired after waking, and its authors called for measures closer to the construct in future work.

sleep midpoint: the halfway point between sleep onset and waking, used as a behavioral indicator of circadian timing.

social jetlag: the difference between mid-sleep time on work or school days and on free days, used as a proxy for mismatch between social schedules and internal timing.

suprachiasmatic nucleus: a paired hypothalamic nucleus that serves as the master circadian pacemaker, receiving light input from the retina and coordinating clocks throughout the body.

wake therapy: therapeutic total or partial sleep deprivation, often combined with light therapy and sleep-phase advance, that can produce rapid but frequently short-lived improvement in depression.

References

Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: Advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 11(10), 1199–1236. https://doi.org/10.5664/jcsm.5100

Carpenter, J. S., Crouse, J. J., Scott, E. M., Naismith, S. L., Wilson, C., Scott, J., Merikangas, K. R., & Hickie, I. B. (2021). Circadian depression: A mood disorder phenotype. Neuroscience & Biobehavioral Reviews, 126, 79–101. https://doi.org/10.1016/j.neubiorev.2021.02.045

Crouse, J. J., Park, S. H., Byrne, E. M., Mitchell, B. L., Chan, K., Scott, J., Medland, S. E., Martin, N. G., Wray, N. R., & Hickie, I. B. (2024). Evening chronotypes with depression report poorer outcomes of selective serotonin reuptake inhibitors: A survey-based study of self-ratings. Biological Psychiatry, 96(1), 4–14. https://doi.org/10.1016/j.biopsych.2023.12.023

Daghlas, I., Lane, J. M., Saxena, R., & Vetter, C. (2021). Genetically proxied diurnal preference, sleep timing, and risk of major depressive disorder. JAMA Psychiatry, 78(8), 903–910. https://doi.org/10.1001/jamapsychiatry.2021.0959

Dhar, P. (2026, October 27). Sleep and depression may be more intertwined than we thought. Scientific American. https://www.scientificamerican.com/article/sleep-and-depression-may-be-more-intertwined-than-we-thought/

Fishbein, A. B., Knutson, K. L., & Zee, P. C. (2021). Circadian disruption and human health. Journal of Clinical Investigation, 131(19), e148286. https://doi.org/10.1172/JCI148286

Geoffroy, P. A., Palagini, L., Henriksen, T. E. G., Bourgin, P., Garbazza, C., Gronfier, C., Esaki, Y., Fernandez, D. C., Lam, R. W., Lee, H.-J., Lejoyeux, M., Maruani, J., Martiny, K., Murray, G., Riemersma-van der Lek, R. F., Ritter, P., Schulte, P. F. J., Smith, D. J., Terman, M., Zeitzer, J. M., & Sit, D. K. (2025). Light therapy for bipolar disorders: Clinical recommendations from the International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force. Dialogues in Clinical Neuroscience, 27(1), 249–264. https://doi.org/10.1080/19585969.2025.2533806

Gottlieb, J. F., Benedetti, F., Geoffroy, P. A., Henriksen, T. E. G., Lam, R. W., Murray, G., Phelps, J., Sit, D., Swartz, H. A., Crowe, M., Etain, B., Frank, E., Goel, N., Haarman, B. C. M., Inder, M., Kallestad, H., Kim, S. J., Martiny, K., Meesters, Y., Porter, R., Riemersma-van der Lek, R. F., Ritter, P. S., Schulte, P. F. J., Scott, J., Wu, J. C., Yu, X., & Chen, S. (2019). The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. Bipolar Disorders, 21(8), 741–773. https://doi.org/10.1111/bdi.12847

Horne, J. A., & Östberg, O. (1976). A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. International Journal of Chronobiology, 4(2), 97–110.

Humpston, C., Benedetti, F., Serfaty, M., Markham, S., Hodsoll, J., Young, A. H., & Veale, D. (2020). Chronotherapy for the rapid treatment of depression: A meta-analysis. Journal of Affective Disorders, 261, 91–102. https://doi.org/10.1016/j.jad.2019.09.078

Keijzer, H., Smits, M. G., Duffy, J. F., & Curfs, L. M. G. (2014). Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Medicine Reviews, 18(4), 333–339. https://doi.org/10.1016/j.smrv.2013.12.001

McGlashan, E. M., Drummond, S. P. A., & Cain, S. W. (2018). Evening types demonstrate reduced SSRI treatment efficacy. Chronobiology International, 35(8), 1175–1178. https://doi.org/10.1080/07420528.2018.1458316

Menegaz de Almeida, A., de Moraes, F. C. A., Souza, M. E. C., Cardoso, J. H. C. O., Tamashiro, F., Miranda, C., Fernandes, L., Kreuz, M., & Kelly, F. A. (2025). Bright light therapy for nonseasonal depressive disorders: A systematic review and meta-analysis. JAMA Psychiatry, 82(1), 38–46. https://doi.org/10.1001/jamapsychiatry.2024.2871

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE Guideline NG222). https://www.nice.org.uk/guidance/ng222/chapter/recommendations

National Institute of Mental Health. (n.d.). Seasonal affective disorder. https://www.nimh.nih.gov/health/publications/seasonal-affective-disorder

Roenneberg, T., Wirz-Justice, A., & Merrow, M. (2003). Life between clocks: Daily temporal patterns of human chronotypes. Journal of Biological Rhythms, 18(1), 80–90. https://doi.org/10.1177/0748730402239679

Sit, D. K., McGowan, J., Wiltrout, C., Diler, R. S., Dills, J., Luther, J., Yang, A., Ciolino, J. D., Seltman, H., Wisniewski, S. R., Terman, M., & Wisner, K. L. (2018). Adjunctive bright light therapy for bipolar depression: A randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 175(2), 131–139. https://doi.org/10.1176/appi.ajp.2017.16101200

Sletten, T. L., Magee, M., Murray, J. M., Gordon, C. J., Lovato, N., Kennaway, D. J., Gwini, S. M., Bartlett, D. J., Lockley, S. W., Lack, L. C., Grunstein, R. R., Rajaratnam, S. M. W., & Delayed Sleep on Melatonin (DelSoM) Study Group. (2018). Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial. PLoS Medicine, 15(6), e1002587. https://doi.org/10.1371/journal.pmed.1002587

Smith, M. T., McCrae, C. S., Cheung, J., Martin, J. L., Harrod, C. G., Heald, J. L., & Carden, K. A. (2018). Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 14(7), 1231–1237. https://doi.org/10.5664/jcsm.7230

Tonini, E., Crouse, J. J., Shin, M., Carpenter, J. S., Mitchell, B. L., Byrne, E. M., Lind, P. A., Gordon, S. D., Parker, R., Hockey, S. J., To, T., Shim, A., Hill, A., Treneman, A., Scott, E., Scott, J., Merikangas, K. R., Wray, N. R., Martin, N. G., Medland, S. E., & Hickie, I. B. (2026). Clinical and genetic correlates of a circadian subtype of depression in the Australian Genetics of Depression Study. The British Journal of Psychiatry. Advance online publication. https://doi.org/10.1192/bjp.2026.10798

Vetter, C., Chang, S.-C., Devore, E. E., Rohrer, F., Okereke, O. I., & Schernhammer, E. S. (2018). Prospective study of chronotype and incident depression among middle- and older-aged women in the Nurses’ Health Study II. Journal of Psychiatric Research, 103, 156–160. https://doi.org/10.1016/j.jpsychires.2018.05.022

Wescott, D. L., Hasler, B. P., Foust, J. E., & Roecklein, K. A. (2025). Circadian realignment and depressed mood: A systematic review. Sleep Medicine Reviews, 79, 102022. https://doi.org/10.1016/j.smrv.2024.102022

About the Author

Fred Shaffer earned his PhD in Psychology from Oklahoma State University. He earned BCIA certifications in Biofeedback and HRV Biofeedback. Fred is an Allen Fellow and Professor of Psychology at Truman State University, where he has taught for 50 years. He is a Biological Psychologist who consults and lectures in heart rate variability biofeedback, Physiological Psychology, and Psychopharmacology. Fred helped to edit Evidence-Based Practice in Biofeedback and Neurofeedback (3rd and 4th eds.) and helps to maintain BCIA's certification programs. He is a recipient of AAPB's Distinguished Scientist Award and BFE's Lifetime Impact Award.

Support Our Friends

Circadian Depression_ When the Body Clock and Mood Fall Out of Step.pdf

Download PDF • 2.91MB